Login
Home / CHMP : OTC
Follow Compare
AI Analysis Fundamentals Valuation Video Analysis News
Quarterly Quarterly (TTM) Annually

AI Analysis

Log in to generate an AI summary for this stock.

Log in to generate a MOAT report for this stock.

Log in to generate an earnings report for this stock.

Log in to generate an operating leverage report for this stock.

Log in to generate a management report for this stock.

Log in to generate a valuation report for this stock.

Champion Industries Inc

$0.02 +$0.00 (+0.00%)
OTC · 14 Sep 2026 20:00 UTC
Previous Close
$0.02
Day Range
$0$0.02
Year Range
$0$0.02
Market Cap
1.13K
AVG Volume
43
Trailing/Forward PE
-0/-
PEG ratio
0
Dividend Yield
-
Next Earnings Date
-
Primary Exchange
Other OTCUS
Revenue (USD)
050M100M150M200M2007200820092010201120122013201420152016
Net Income (USD)
-30M-20M-10M010M2007200820092010201120122013201420152016
Operating Income (USD)
-40M-20M020M2007200820092010201120122013201420152016
EBITDA (USD)
-40M-20M020M2007200820092010201120122013201420152016
Cash Flows (USD)
-5M05M10M2007200820092010201120122013201420152016
EPS (USD)
-600-400-20002002007200820092010201120122013201420152016
Expenses (USD)
020M40M60MSG&ACapex2007200820092010201120122013201420152016
Cash & Debt (USD)
025M50M75M100MCashLong Term DebtShort Term Debt2007200820092010201120122013201420152016
Debt ratios
-20-1001020092010201120122013201420152016
Margins
0%10%20%30%40%2007200820092010201120122013201420152016
Return on Capital
-500%0%500%1000%1500%2000%2007200820092010201120122013201420152016
Shares Outstanding
020K40K60K2007200820092010201120122013201420152016
Dividends (USD)
02040601999200020012002200320042005200620072008
Book Value Per Share (USD)
-5000500100015002007200820092010201120122013201420152016
Total Assets (USD)
050M100M150M2007200820092010201120122013201420152016
PE Ratio
010203040med 0.92Jun 11Oct 11Jan 12May 14Aug 14Nov 14Mar 15
Free Cash Flow Yield
0%5000000%10000000%15000000%med 12992854.94%Jan 25May 25Sep 25Jan 26May 26Sep 26
Price to Sales
00000med 0Dec 24Apr 25Jul 25Nov 25Feb 26Jun 26Sep 26
EV/EBITDA
9.439.439.439.43med 9.43Dec 24Apr 25Jul 25Nov 25Feb 26Jun 26Sep 26
Price/Operating Cashflow
00000med 0Dec 24Apr 25Jul 25Nov 25Feb 26Jun 26Sep 26
Price to Book
00000med 0Dec 24Apr 25Jul 25Nov 25Feb 26Jun 26Sep 26
Champion Industries Inc
CHMP
Stockpicker

Video analysis: CHMP

All videos

No video analysis for this stock yet. Request one from our team.

Your email is used only to follow up on this request. We do not add you to marketing lists. Privacy Policy

News: CHMP

Scholar Rock Reports Second Quarter 2026 Financial Results and Recent Business Highlights

gurufocus.com · 6 Aug 2026

Scholar Rock Reports Second Quarter 2026 Financial Results and Recent Business Highlights

Scholar Rock (NASDAQ: SRRK), a global biopharmaceutical company dedicated to improving the lives of patients with rare, severe, and debilitating neuromuscular d
AbbVie Receives Positive CHMP Opinion for Upadacitinib (RINVOQ®) for the Treatment of Adults and Adolescents with Severe Alopecia Areata

gurufocus.com · 29 Jun 2026

AbbVie Receives Positive CHMP Opinion for Upadacitinib (RINVOQ®) for the Treatment of Adults and Adolescents with Severe Alopecia Areata

AbbVie Receives Positive CHMP Opinion for Upadacitinib (RINVOQÂ) for the Treatment of Adults and Adolescents with Severe Alopecia Areata
Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis

gurufocus.com · 26 Jun 2026

Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis

Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positi
Lilly's Jaypirca (pirtobrutinib) recommended by CHMP for approval in the European Union for adults with chronic lymphocytic leukemia (CLL) across all lines of therapy

gurufocus.com · 26 Jun 2026

Lilly's Jaypirca (pirtobrutinib) recommended by CHMP for approval in the European Union for adults with chronic lymphocytic leukemia (CLL) across all lines of therapy

Lilly's Jaypirca (pirtobrutinib) recommended by CHMP for approval in the European Union for adults with chronic lymphocytic leukemia (CLL) acro
Disclaimer: The historical data presented on this platform is provided by Financial Modeling Prep. Stock Picker is a platform for informational purposes only and does not provide financial advice. Users are encouraged to conduct their own research and consult with a qualified financial advisor before making investment decisions.